bluebird bio (BLUE) Short Interest Ratio & Short Volume $0.30 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends bluebird bio Short Interest Databluebird bio (BLUE) has a short interest of 47.71 million shares. This marks a -3.46% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.3, indicating that it would take 6.3 days of the average trading volume of 7.39 million shares to cover all short positions.Current Short Interest47,710,000 sharesPrevious Short Interest49,420,000 sharesChange Vs. Previous Month-3.46%Dollar Volume Sold Short$22.14 millionShort Interest Ratio6.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares194,440,000 sharesPercentage of Shares Shorted24.54%Today's Trading Volume3,446,554 sharesAverage Trading Volume7,392,469 sharesToday's Volume Vs. Average47% Short Selling bluebird bio? Sign up to receive the latest short interest report for bluebird bio and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBLUE Short Interest Over TimeBLUE Days to Cover Over TimeBLUE Percentage of Float Shorted Over Time Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! bluebird bio Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202447,710,000 shares $22.14 million -3.5%N/A6.3 $0.46 10/15/202449,420,000 shares $23.78 million +0.9%N/A6.8 $0.48 9/30/202448,990,000 shares $25.45 million +1.2%N/A6.4 $0.52 9/15/202448,400,000 shares $29.32 million -2.0%N/A6.5 $0.61 8/31/202449,370,000 shares $27.72 million +20.0%N/A6.8 $0.56 8/15/202441,140,000 shares $29.02 million +32.2%N/A6.1 $0.71 Get the Latest News and Ratings for BLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. 7/31/202431,130,000 shares $36.11 million +1.2%N/A5.6 $1.16 7/15/202430,770,000 shares $40.62 million +0.2%N/A5 $1.32 6/30/202430,710,000 shares $30.22 million +4.2%N/A4.9 $0.98 6/15/202429,480,000 shares $28.29 million +1.2%N/A4.7 $0.96 5/31/202429,120,000 shares $26.31 million -7.9%N/A4.5 $0.90 5/15/202431,600,000 shares $33.81 million -0.8%N/A4 $1.07 4/30/202431,860,000 shares $28.26 million -2.3%N/A3.8 $0.89 4/15/202432,620,000 shares $33.60 million +9.7%N/A3.8 $1.03 3/31/202429,750,000 shares $38.08 million -12.6%N/A3.3 $1.28 3/15/202434,040,000 shares $48.34 million -0.3%N/A3.2 $1.42 2/29/202434,130,000 shares $47.44 million +19.4%N/A2.4 $1.39 2/15/202428,590,000 shares $30.88 million +4.0%N/A2.2 $1.08 1/31/202427,500,000 shares $28.05 million +3.5%N/A2.3 $1.02 1/15/202426,570,000 shares $39.86 million +10.3%N/A2.4 $1.50 12/31/202324,090,000 shares $33.24 million -5.4%N/A2.4 $1.38 12/15/202325,470,000 shares $83.29 million +16.6%N/A2.8 $3.27 11/30/202321,850,000 shares $83.47 million -2.9%N/A4.7 $3.82 11/15/202322,490,000 shares $73.99 million -8.5%N/A6.4 $3.29 10/31/202324,570,000 shares $72.48 million -0.4%N/A7 $2.95 10/15/202324,670,000 shares $65.62 million +2.3%N/A7 $2.66 9/30/202324,110,000 shares $73.29 million -17.0%N/A5.8 $3.04 9/15/202329,040,000 shares $97.28 million +11.5%N/A7 $3.35 8/31/202326,040,000 shares $98.17 million -1.6%N/A6.3 $3.77 8/15/202326,450,000 shares $95.75 million -8.3%N/A6.2 $3.62 7/31/202328,840,000 shares $113.34 million +13.7%N/A6.6 $3.93 7/15/202325,360,000 shares $76.84 million -21.5%N/A5.8 $3.03 6/30/202332,300,000 shares $106.27 million +6.1%N/A8.1 $3.29 6/15/202330,440,000 shares $121.46 million +23.0%N/A6.8 $3.99 5/31/202324,740,000 shares $82.88 million +5.3%N/A5.2 $3.35 5/15/202323,490,000 shares $96.78 million -0.3%N/A5 $4.12 4/30/202323,550,000 shares $102.44 million -0.8%N/A5.3 $4.35 4/15/202323,740,000 shares $74.07 million -10.3%N/A5.5 $3.12 3/31/202326,450,000 shares $84.11 million +29.0%N/A6.1 $3.18 3/15/202320,510,000 shares $95.37 million +12.2%N/A5.4 $4.65When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! 2/28/202318,280,000 shares $95.06 million +5.5%N/A5.4 $5.20 2/15/202317,320,000 shares $102.88 million +0.2%N/A5.1 $5.94 1/31/202317,290,000 shares $109.79 million -6.3%N/A4.7 $6.35 1/15/202318,450,000 shares $145.57 million +1.2%N/A4.9 $7.89 12/30/202218,240,000 shares $126.22 million -1.1%N/A5.3 $6.92 12/15/202218,450,000 shares $143.54 million +1.0%N/A4.6 $7.78 11/30/202218,270,000 shares $142.32 million -5.2%N/A3.3 $7.79 11/15/202219,270,000 shares $148.38 million -14.5%N/A3.2 $7.70 10/31/202222,540,000 shares $141.33 million +0.5%N/A3.1 $6.27 10/15/202222,440,000 shares $143.39 million -1.2%N/A2.9 $6.39 9/30/202222,710,000 shares $143.75 million +13.0%N/A2.9 $6.33 9/15/202220,100,000 shares $142.51 million +1.8%N/A2.4 $7.09 8/31/202219,740,000 shares $115.28 million +19.9%N/A2 $5.84 8/15/202216,460,000 shares $112.42 million +8.4%N/A1.8 $6.83 7/31/202215,190,000 shares $61.52 million +13.3%N/A2 $4.05 7/15/202213,410,000 shares $64.50 million -11.1%N/A2 $4.81 6/30/202215,090,000 shares $62.47 million -13.8%N/A2.3 $4.14 6/15/202217,510,000 shares $60.93 million +39.0%32.1%3.2 $3.48 5/31/202212,600,000 shares $40.32 million +1.9%N/A5.2 $3.20 5/15/202212,370,000 shares $44.16 million +1.8%N/A5.3 $3.57 4/30/202212,150,000 shares $44.10 million +6.6%N/A5.4 $3.63 4/15/202211,400,000 shares $51.76 million -0.7%N/A4.8 $4.54 3/31/202211,480,000 shares $55.68 million +43.7%N/A4.8 $4.85 3/15/20227,990,000 shares $35.72 million +9.2%N/A3.1 $4.47 2/28/20227,320,000 shares $44.21 million +2.0%N/A3.1 $6.04 2/15/20227,180,000 shares $48.68 million +3.2%N/A3.1 $6.78 1/31/20226,960,000 shares $54.91 million +1.0%N/A2.8 $7.89 1/15/20226,890,000 shares $60.15 million +19.0%N/A2.9 $8.73 12/31/20215,790,000 shares $57.84 million +4.3%N/A2.8 $9.99 12/15/20215,550,000 shares $52.78 million -3.3%N/A2.8 $9.51 11/30/20215,740,000 shares $58.03 million +6.3%N/A3.9 $10.11 11/15/20215,400,000 shares $61.99 million +5.9%N/A3.8 $11.48 10/29/20215,100,000 shares $119.39 million -11.5%7.8%3.9 $23.41 10/15/20215,760,000 shares $120.38 million -0.2%8.8%4.9 $20.90 9/30/20215,770,000 shares $110.26 million +10.5%8.8%5.1 $19.11 9/15/20215,220,000 shares $92.92 million -8.6%7.9%3.8 $17.80 8/31/20215,710,000 shares $104.49 million -9.7%8.7%4 $18.30 8/13/20216,320,000 shares $116.73 million +1.1%9.6%4.5 $18.47 7/30/20216,250,000 shares $158.81 million +6.5%9.5%4.4 $25.41 7/15/20215,870,000 shares $161.60 million -7.3%8.9%4.7 $27.53 6/30/20216,330,000 shares $202.43 million +18.3%9.6%4.8 $31.98 6/15/20215,350,000 shares $175.64 million +4.7%8.1%4.1 $32.83 5/28/20215,110,000 shares $159.02 million -13.4%7.7%3.8 $31.12 5/14/20215,900,000 shares $172.93 million -7.1%N/A3.3 $29.31 4/30/20216,350,000 shares $191.96 million -4.4%N/A2.8 $30.23 4/15/20216,640,000 shares $196.15 million -2.1%N/A2.9 $29.54 3/31/20216,780,000 shares $194.04 million +25.3%N/A2.9 $28.62 3/15/20215,410,000 shares $175.45 million -14.7%N/A2.5 $32.43 2/26/20216,340,000 shares $178.28 million +4.1%N/A3.2 $28.12 2/12/20216,090,000 shares $278.74 million +2.4%N/A3.6 $45.77When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! 1/29/20215,950,000 shares $267.75 million -3.1%N/A4.8 $45.00 1/15/20216,140,000 shares $318.36 million -15.0%N/A5.1 $51.85 12/31/20207,220,000 shares $318.47 million +3.9%N/A6.6 $44.11 12/15/20206,950,000 shares $309.62 million +1.6%N/A7 $44.55 11/30/20206,840,000 shares $301.37 million +0.2%N/A7.4 $44.06 11/15/20206,830,000 shares $314.25 million +7.7%N/A7.9 $46.01 10/30/20206,340,000 shares $335.32 million +3.1%N/A7.8 $52.89 10/15/20206,150,000 shares $343.11 million +0.5%N/A9.1 $55.79 9/30/20206,120,000 shares $330.17 million -0.7%N/A8.9 $53.95 9/15/20206,160,000 shares $327.77 million -10.1%N/A7.9 $53.21 8/31/20206,850,000 shares $406.21 million -0.3%N/A8 $59.30 8/14/20206,870,000 shares $409.93 million -2.1%N/A7.3 $59.67 7/31/20207,020,000 shares $426.11 million +0.7%N/A5.8 $60.70 7/15/20206,970,000 shares $459.39 million -5.2%N/A5.2 $65.91 6/30/20207,350,000 shares $448.64 million -2.7%N/A4.9 $61.04 6/15/20207,550,000 shares $479.73 million -0.5%N/A5.1 $63.54 5/29/20207,590,000 shares $482.95 million -1.0%N/A5.2 $63.63 5/15/20207,670,000 shares $434.58 million +3.4%13.9%5.3 $56.66 4/30/20207,420,000 shares $399.79 million -2.2%13.5%6.2 $53.88 4/15/20207,590,000 shares $359.54 million -0.9%13.8%6.9 $47.37 3/31/20207,660,000 shares $448.72 million -1.0%13.9%7.5 $58.58 3/13/20207,736,600 shares $359.75 million -3.7%14.1%10.1 $46.50 2/28/20208,030,000 shares $380.94 million -1.1%14.6%7.4 $47.44 2/14/20208,120,000 shares $537.30 million -2.5%N/A6.9 $66.17 1/31/20208,330,000 shares $605.59 million -2.6%15.2%6.7 $72.70 1/15/20208,550,000 shares $770.01 million -0.1%15.6%6.7 $90.06 12/31/20198,560,000 shares $746.95 million -0.6%15.6%7.3 $87.26 BLUE Short Interest - Frequently Asked Questions What is bluebird bio's current short interest? Short interest is the volume of bluebird bio shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 47,710,000 shares of BLUE short. Learn More on bluebird bio's current short interest. What is a good short interest ratio for bluebird bio? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BLUE shares currently have a short interest ratio of 6.0. Learn More on bluebird bio's short interest ratio. Is bluebird bio's short interest increasing or decreasing? bluebird bio saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 47,710,000 shares, a decline of 3.5% from the previous total of 49,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does bluebird bio's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to bluebird bio: AlloVir, Inc. (3.42%), Tevogen Bio Holdings Inc. (16.80%), TScan Therapeutics, Inc. (5.19%), Sutro Biopharma, Inc. (2.91%), Molecular Partners AG (0.14%), SOPHiA GENETICS SA (0.05%), Genfit S.A. (0.13%), Inhibrx, Inc. (9.70%), Zura Bio Limited (4.14%), Editas Medicine, Inc. (20.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short bluebird bio stock? Short selling BLUE is an investing strategy that aims to generate trading profit from bluebird bio as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against bluebird bio? A short squeeze for bluebird bio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BLUE, which in turn drives the price of the stock up even further. How often is bluebird bio's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BLUE, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies AlloVir Short Interest Data Tevogen Bio Short Interest Data TScan Therapeutics Short Interest Data Sutro Biopharma Short Interest Data Molecular Partners Short Interest Data SOPHiA GENETICS Short Interest Data Genfit Short Interest Data Inhibrx Short Interest Data Zura Bio Short Interest Data Editas Medicine Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BLUE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
